



Immuron to Present at the RedChip Global Online Microcap Conference

22nd October, 2015 – Melbourne, Australia: Mr Thomas Liquard, CEO of Immuron Limited (ASX: IMC; OTC US: IMROY), is scheduled to present at the RedChip Global Online Microcap Conference on Thursday 22nd October, 2015, at 9:30AM US Eastern time. The presentation can be viewed at www.RedChip.com.

A live Q&A session will follow the investor presentation. Investors can pre-submit their questions by visiting <http://www.redchip.com/events/3/global-online-microcap-conference>.

The RedChip Global Online Microcap Conference brings together investors and executives of leading microcap companies, representing a broad spectrum of industries and sectors, including oil & gas, technology, mining, healthcare, consumer goods, energy, and more. More than 10,000 investors attend RedChip's microcap conference series each year.

No registration is required to participate in the conference. Start times are subject to change.

As previously announced, Immuron engaged Red Chip for the provision of certain US Investor Relations Services. On 20th August 2015 Red Chip released an Analyst Report which attracted significant online and market attention. A copy of this report is available at www.immuron.com/index.php/download_file/-/view/140/.

Contact:

Thomas Liquard
Chief Executive Officer

AUS Ph: +61 (0)3 9824 5254

Email: thomasliquard@immuron.com

Jon Cunningham

RedChip Companies, Inc.

US Tel: 0011 1-800-RED-CHIP (733-2447), ext. 107

Email: info@redchip.com

About RedChip Companies, Inc.

RedChip Companies, an Inc. 5000 company, is an international small-cap research, investor relations, and media company headquartered in Orlando, Florida with affiliate offices in San Francisco, Pittsburgh, and Seoul. RedChip delivers concrete, measurable results for its clients through its extensive global network of small-cap institutional and retail investors. RedChip has developed the most comprehensive platform of products and services for small-cap companies, including: RedChip Research™, Traditional Investor Relations, Digital Investor Relations, Institutional and Retail Conferences, Virtual Conferences, "The RedChip Money Report: Small Stocks Big Money"™ television show, Shareholder Intelligence, Strategic Marketing, Crisis Management, Social Media and Blogging Services, and Webcasts. www.redchip.com

The Immuron logo is located in the top right corner. It consists of the word "Immuron" in a blue, sans-serif font, followed by a circular icon containing a stylized white 'e' shape.

Immuron

COMPANY PRESENTATION

October 2015

Forward-Looking Statement

Certain statements made in this presentation are forward-looking statements and are based on Immuron's current expectations, estimates and projections. Words such as "anticipates," "expects," "intends," "plans," "believes," "seeks," "estimates," "guidance" and similar expressions are intended to identify forward-looking statements.

Although Immuron believes the forward-looking statements are based on reasonable assumptions, they are subject to certain risks and uncertainties, some of which are beyond Immuron's control, including those risks or uncertainties inherent in the process of both developing and commercializing technology. As a result, actual results could materially differ from those expressed or forecasted in the forward-looking statements.

The forward-looking statements made in this presentation relate only to events as of the date on which the statements are made. Immuron will not undertake any obligation to release publicly any revisions or updates to these forward-looking statements to reflect events, circumstances or unanticipated events occurring after the date of this presentation except as required by law or by any appropriate regulatory authority.

Corporate Overview

- **Unique and Leverageable Platform** – Proprietary oral immunotherapy technology targeting microbiome and inflammation with broad utility
- **Attracting Leading Collaborations** – NIH, Renowned experts and institutions
- **Strong Pipeline** – High value indications, with leading competitive profiles
 - **Phase II in NASH (Fatty-Liver Disease)**
 - Targeted End of enrollment: 2Q16; Top Line results: 4Q16 – 1Q17
 - Two unique inflammatory modulating mechanisms: (1) Binds to LPS, (2) Promotes regulatory T-Cell; Restores normal liver function and reverses fibrosis
 - No approved therapy, \$40B market by 2025
 - **C-Difficile program targeting the 3 key infectious cycles (Toxin B, Spores, and Vegetative cells) in pre-clinical stage**
 - Developed in collaboration with world renown C-difficile team at Monash
 - Phase 1/2 start anticipated in 1H2016
- **Generating Growing Revenues** – Travelan™ for Traveler's Diarrhea
- **Significantly Undervalued** – Substantial upside exist for investors

Investment Highlights

Immuron Is a Compelling Investment Opportunity...

NASH and ASH:	Two Phase II studies in progress with an increasingly alluring potential upside
Travelan:	Revenues growing and positioned to grow further with successful USA launch
Pipeline:	Progressing; potential for multi-billion \$ assets
Cap Profile:	Robust
Financials:	Debt free, cash in the bank until after completion of NASH trial

... With Significant Room for Valuation Upside NASH Peer Comparables


NASH Peer Comparables					
Company Name	Ticker	Share Price (USD)	Market Cap (USD)	Cash (MRQ, USD)	Total Debt (MRQ, USD)
Intercept Pharmaceuticals Inc	ICPT	\$213.99	\$5,179.M	\$732.3M	\$0.0
Raptor Pharmaceutical Corp	RPTP	\$13.35	\$1,083.8M	\$220.5M	\$117.0M
Genfit SA	GNFT	\$40.08	\$960.2M	\$28.8M	N/A
Enanta Pharmaceuticals Inc	ENTA	\$40.41	\$756.2M	\$154.2M	\$0.4M
Ardelyx Inc	ARDX	\$18.21	\$472.1M	\$141.5M	\$0.0
Galmed Pharmaceuticals Ltd	GLMD	\$9.15	\$101.6M	\$29.9M	\$0.0
MediciNova Inc	MNOV	\$3.60	\$89.6M	\$8.6M	\$0.0
Conatus Pharmaceuticals Inc	CNAT	\$4.15	\$81.8M	\$31.0M	\$1.0M
Viking Therapeutics Inc	VKTX	\$7.31	\$71.5M	\$0.3M	\$1.7M
Galectin Therapeutics Inc	GALT	\$2.70	\$61.5M	\$26.3M	\$1.6M
Islet Sciences Inc	ISLT	\$0.04	\$2.8M	\$0.02M	\$0.05M
	<i>median</i>		\$101.6M	\$29.9M	\$0.2M
	<i>average</i>		\$805.5M	\$124.9M	\$12.2M

Strong Financial Position:

- Ticker Code: IMC.AX (Australia)
- Share price: (as at 22 October 2015) AUD\$0.51; USD\$0.37
- Shares outstanding: 75M
- Market Cap: AUD\$40M; USD\$29M
- Cash: (as of 30 June 2015) \$3.1M
- Debt: \$0

Immuron

PIPELINE




Portfolio

- **IMM-124E (anti LPS + adjuvants) for NASH**
- IMM-529 for Clostridium Difficile

IMM-124E

Compelling MOA in NASH

NASH – Pathogenesis




Immuron

IMM-124E – MOA

Unique Properties

- Increased concentration of immunoglobulin (mainly IgG)
- Strong anti-LPS properties, Cross reactive
- Immune-reactive adjuvants that promote regulatory T-Cells that suppress systemic inflammation
- Not absorbed in the blood
- Immune modulation without immune suppression



Decrease systemic and local inflammation

Decreases liver inflammation - Improves liver function

IMM-124E In NASH

Fibrotic Liver



IMM-124E


IMM-124E Treated Liver





Mizrahi M. 2013, AASLD; Hepatology 751A

IMM-124E - Improves Inflammation and Fibrosis Markers


Immuron



Decreased Portal Inflammation




Improved Metavir Fibrosis Score




IMM-124E Clinical Improves Liver Function and Insulin Resistance

Results of a Phase I/IIA clinical trial; N=10

Improved Liver Enzymes



Improved HbA1C, OGTT and HOMA



NASH – A \$35B - \$40B Market Major Commercial Opportunity

- 25% of the US population has NAFLD
- 5% of the population will develop NASH
- No treatments approved
- All major pharma looking to get into the game
- Most treatments
 - Do not capture the entire disease population
 - Limited efficacy
 - Severe / unknown side effect profile


Estimated Market Size: \$35B - \$40B USD by 2025 (Deutsche Bank)

PORTFOLIO

- IMM-124E (anti LPS + adjuvants) for NASH
- **IMM-529 for Clostridium Difficile**

C-Difficile – A Significant Unmet Need


Center for Disease Control (CDC)
Antibiotic Resistance Threats in the United States, 2013




IMM-529 – Toxin B Vaccine Specially Developed to Defeat C-Diff

- IMM-529 is combination vaccine that targets: Toxin B, C-Diff spores and C-Diff vegetative cells
- Murine studies performed at Monash University, Australia:
 - Prophylaxis – Demonstrating effectiveness in **80% of cases**
 - Treatment – Prevented death in **80% of cases**

Prophylaxis



Treatment



The Immuron logo is located in the top right corner. It consists of the word "Immuron" in a blue, sans-serif font, followed by a circular icon containing a stylized white 'e' shape.

Immuron

The background of the advertisement is a blue-tinted illustration of a human torso. The internal organs, including the lungs, liver, stomach, and intestines, are depicted in a semi-transparent, glowing blue style. The large intestine is specifically highlighted with a vibrant orange-to-yellow gradient, making it stand out from the other organs.

TRAVELAN®

Stop it before it starts

Travelan® A Unique Preventative Product



The only therapy that prevents Travelers' Diarrhea by up to 90%

Without Travelan®:
Bacteria attach to gut wall and infect



With Travelan®: Bacteria neutralized by Travelan® antibodies



- Marketed in the US, Australia by Immuron and by Paladin/Endo in Canada
- Global market estimate: US\$ 600M - 1.2B
- All-natural product;
- Clinically proven
- SAFE
- OTC
- Strong brand loyalty
- Multiple life-cycle opportunities

Travelan®

—— Status 06/2015


→ Progress in 07/2015 – 06/2016

Country	Discussions	Term Sheet	Licensed	Regulatory	In Market
Canada					
South Korea					
Other Asian Countries					
United States					
India					
China					

* Regulatory application preceding partnering engagement

Immuron

SUMMARY



Investment Highlights

Immuron Is a Compelling Investment Opportunity

NASH and ASH:	Two Phase II studies in progress with an increasingly alluring potential upside
Travelan:	Revenues growing and positioned to grow further with successful USA launch
Pipeline:	Progressing; potential for multi-billion \$ assets
Cap Profile:	Robust
Financials:	Debt free, cash in the bank until after completion of NASH trial

Corporate Structure

The Board and Management

Dr Roger Aston
Chairman

Roger has more than 20 years of experience in the pharmaceutical and biotech industries. He was the Founding Chief Executive Officer and a Director of Mayne Pharma Group Limited.

Daniel Pollock
Non-executive Director

Daniel is an internationally experienced lawyer admitted in both Scotland and Australia, with significant commercial expertise in overseas new market entries, distribution agreements and corporate start-ups.

Stephen Anastasiou
Non-executive Director

Stephen has extensive experience in general management, marketing and strategic planning in the healthcare industry, formerly with KPMG.

Thomas Liquard
Chief Executive Officer

Thomas spent the majority of his career at Pfizer in New York in various commercial positions and was COO then CEO of Alchemia Limited, an oncology ASX biotech company.

Dan Peres, MD
Head of Medical

Dan had been leading Medical Device and Pharma companies in their clinical stage since 2008. a Physician in origin has years of experience in management and medical development.

Jerry Kanellos, PhD
COO & Scientific Officer

Dr Jerry Kanellos has over 20 years of experience in the pharmaceutical and biotech industries including CMC, operations and business development. He has held senior roles at CSL and Transbio Limited.

Neta Tobis
Clinical Director

With over 7 years' experience of international trial management for small to large pharma and medical device companies as well as working within large CROs (PPD).

Reza Moussakhani
Manufacturing Quality Director

A professional Operations manager with extensive experience in implementation of project / quality and process improvements including with Hospira and Sigma Pharmaceuticals.

Dr. Yaron Ilan
Medical and Scientific Advisor

Dr. Yaron Ilan, MD, is a Director-Inpatient Medicine Department at Hadassah Medical Center. He holds more than 50 patents and co-authored more than 240 articles.

An anatomical illustration of a human torso, showing the internal organs. The liver is highlighted in a reddish-orange color, and the large intestine is shown in a similar color. The rest of the body is rendered in a translucent blue color. The background is a solid blue color.

Immuron

THANK YOU